Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Avalo Reports 2023 Financial Results and Provides Business Updates tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Avalo Therapeutics shares are soaring after acquiring AVTX-009, a Phase 2-ready anti-IL-1β mAb. With $185 million in gross proceeds, Avalo aims to develop AVTX-009 for hidradenitis suppurativa and other chronic inflammatory indications. Chairman Garry Neil believes AVTX-009 holds immense potential in the multi-billion-dollar HS market.
Avalo Therapeutics Inc (NASDAQ:AVTX) shares are skyrocketing as the company on Wednesday announced the acquisition of a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio Inc. Avalo announced a private placement of $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million. Avalo intends to pursue the development of AVTX-009 in hidradenitis suppurativa (HS). Topline results from a planned Phase 2
Avalo snaps up AlmataBio for ex-Lilly inflammatory drug fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.